Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access

Identifying Needs: a Qualitative Study of women’s Experiences Regarding Rapid Genetic Testing for Hereditary Breast and Ovarian Cancer in the DNA BONus Study

(2016) Mirjam Tonheim Augestad et al.   Journal of Genetic Counseling

New paradigms forBRCA1/BRCA2testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study

(2016) Inga Plaskocinska et al.   JOURNAL OF MEDICAL GENETICS

Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? results from a randomized clinical trial

(2015) Marijke R. Wevers et al.   GENETICS IN MEDICINE

Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates

(2015) Sam Watts et al.   BMJ Open

Differential mental health impact of cancer across racial/ethnic groups: findings from a population-based study in California

(2014) Héctor E Alcalá   BMC PUBLIC HEALTH

Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial

(2014) M R Wevers et al.   BRITISH JOURNAL OF CANCER

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Are we being overly cautious? A qualitative inquiry into the experiences and perceptions of treatment-focused germline BRCA genetic testing amongst women recently diagnosed with breast cancer

(2012) E. Zilliacus et al.   SUPPORTIVE CARE IN CANCER

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

(2011) Shiyu Zhang et al.   GYNECOLOGIC ONCOLOGY

There is no decision to make: Experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer

(2011) B. Meiser et al.   GYNECOLOGIC ONCOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

(2010) Susan M. Domchek   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

(2009) T. R. Rebbeck et al.   JNCI-Journal of the National Cancer Institute

Distress in couples approached for genetic counseling andBRCA1/2testing during adjuvant radiotherapy

(2009) Kathryn J. Schlich-Bakker et al.   PSYCHO-ONCOLOGY

Uptake of clinical genetic testing for ovarian cancer in Ontario: A population-based study

(2008) Kelly A. Metcalfe et al.   GYNECOLOGIC ONCOLOGY

Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study

(2008) Noah D. Kauff et al.   JOURNAL OF CLINICAL ONCOLOGY